However, dovitinib did not show clinical benefit in endometrial cancer with FGFR2 mutations, glioblastoma with FGFR3‐TACC3 gene fusion and urothelial carcinoma with FGFR3 mutations or overexpression.63, 152. The gene discussed is TACC3; the disease is urothelial carcinoma.